WallStSmart
NRXS

Neuraxis, Inc.

AMEX: NRXS · HEALTHCARE · BIOTECHNOLOGY

$8.20
-5.91% today

Updated 2026-06-05

Market cap
$84.21M
P/E ratio
P/S ratio
19.67x
EPS (TTM)
$-0.80
Dividend yield
52W range
$2 – $9
Volume
0.2M

Neuraxis, Inc. (NRXS) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item202020212022202320242025
Revenue$1.93M$2.72M$2.68M$2.46M$2.69M$3.57M
Revenue growth (YoY)+41.0%-1.3%-8.4%+9.2%+32.9%
Cost of revenue$481089.00$467656.00$297060.00$303345.00$362002.00$562916.00
Gross profit$1.45M$2.25M$2.39M$2.16M$2.32M$3.01M
Gross margin75.1%82.8%88.9%87.7%86.5%84.2%
R&D$166798.00$203414.00$225610.00$169315.00$206107.00$493611.00
SG&A$4.88M$4.56M$5.12M$8.33M$8.95M$8.06M
Operating income$-4.12M$-2.97M$-3.37M$-6.66M$-7.16M$-7.83M
Operating margin-213.5%-109.1%-125.6%-270.9%-266.5%-219.4%
EBITDA$-3.61M$-2.95M$-4.33M$-9.23M$-7.90M$-7.67M
EBITDA margin-187.3%-108.6%-161.1%-375.1%-294.2%-214.8%
EBIT$-3.65M$-2.99M$-4.36M$-9.27M$-7.94M$-7.73M
Interest expense$75711.00$36928.00$417601.00$5.36M$300715.00$73969.00
Income tax$324063.00$45200.00$429557.00$5.36M$-8.24M
Effective tax rate-9.5%-1.5%-9.9%-57.9%50.0%0.0%
Net income$-3.73M$-3.03M$-4.78M$-14.63M$-8.24M$-7.80M
Net income growth (YoY)+18.7%-57.9%-206.0%+43.7%+5.4%
Profit margin-193.0%-111.3%-178.0%-594.6%-306.8%-218.5%

Frequently asked questions

What is Neuraxis, Inc.'s revenue?

Neuraxis, Inc.'s trailing twelve-month revenue is $4.28M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is NRXS?

In its most recent fiscal year, NRXS ran a gross margin of 84.23%, an operating margin of -219.37%, and a net margin of -218.55%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does NRXS generate?

NRXS produced $-6.46M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is NRXS's balance sheet healthy?

NRXS holds $4.97M in cash and equivalents against — in long-term debt, on $3.40M of shareholder equity. That debt is best read against the cash flow the business throws off each year.